{
  "document_id": "CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement",
  "file_path": "data/CUAD_v1/full_contract_pdf/Part_I/Development/CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement.pdf",
  "text_length": 145858,
  "chunk_count": 193,
  "vector_store_path": "output/vector_stores/CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement",
  "summary": "the Territory, negotiation of wholesaler contracts and negotiations with buyer groups (including group purchasing organizations) and\nkey accounts\u037e (c) negotiating with public and private health insurance companies and governmental authorities regarding the price and\nreimbursement status of the Licensed Products and obtaining and maintaining pricing and reimbursement approvals\u037e (d) marketing,\nmedical affairs, and promotion (including by entertaining a dedicated and sufficiently qualified sales staff, providing for appropriate\nincentive mechanisms for such sales staff, attending relevant conferences, interacting with key opinion leaders, etc.)\u037e (e) set-up of hub\nservices including pre-authorization and reimbursement support and co-pay assist programs\u037e (f) booking of sales and performance of\nrelated services\u037e (g) handling all aspects of order processing, invoicing and collection, inventory and receivables\u037e (h) providing\n\nAgreement shall control, unless otherwise explicitly agreed to in writing by the Parties.\n16.11 Entire Agreement . This Agreement (including the attached Annexes and Schedules) together with the\nManufacturing and Supply Agreement and the Pharmacovigilance Agreement described in Section 4.6 contains the entire\nunderstanding of the Parties with respect to the subject matter hereof. To the extent of any conflict between the terms and conditions\nof this Agreement and the terms and conditions of the Manufacturing and Supply Agreement or Pharmacovigilance Agreement, the\nterms and conditions of this Agreement shall control unless otherwise expressly set forth to the contrary in the Manufacturing and\nSupply Agreement or Pharmacovigilance Agreement. All other express or implied representations, agreements and understandings\nwith respect to the subject matter hereof, either oral or written, heretofore made, are expressly superseded by this Agreement.\n\nLicensee\u2019s Net Sales reporting to its licensors on a confidential basis to the extent required under the relevant agreements with such\nlicensors.\n7.3.3 Calculation of Gross Margin from Net Sales . With respect to the calculation of aggregate Gross Margins\nachieved from the total amount of Net Sales of a Licensed Product in the Territory in a given calendar quarter (the Quarterly Net\nSales Amount ):\n(a) Licensee shall first deduct from the Quarterly Net Sales Amount [***] an amount equal to the supply\nprice paid by Licensee to Bioeq (pursuant to the Manufacturing and Supply Agreement) for the supply of all such Licensed Product\nsold in the Territory for such calendar quarter [***]\u037e\n(b) From such amount resulting after the application of Section 7.3.3(a) above, Licensee shall deduct (i) all\nDamages which have actually been paid by Licensee or its Affiliates to a non-Defendant Third Party, (ii) all Qualifying IP Clearance\n\nConfidential\nExecution Version\na written report setting forth in reasonable detail, on a Licensed Product-by-Licensed Product basis, the calculation of (a) the\naggregate Net Sales achieved for such Licensed Product in such calendar quarter (including a detailed description of invoiced gross\nsales prices and all deductions made pursuant to Section 1.49), (b) the aggregate Gross Margins achieved for such Licensed Product\nin such calendar quarter (including a detailed description of all deductions and calculations made pursuant to Section 7.3.3 in arriving\nat such Gross Margin calculation), and (c) the calculation of the royalties owing by Licensee to Bioeq pursuant to Section 7.3 for such\ncalendar quarter. Notwithstanding the Parties\u2019 confidentiality obligations pursuant to Section 11, Bioeq shall have the right to report\nLicensee\u2019s Net Sales reporting to its licensors on a confidential basis to the extent required under the relevant agreements with such\nlicensors.",
  "parties": "special, non-compensatory, consequential, indirect, incidental, statutory or punitive damages have been awarded to a Third Party under\na Third Party Claim.\n14.GOVERNANCE\n14.1 Committees . The Parties shall, within [***] ([***]) days following the Effective Date, establish (a) a\nDevelopment and Manufacturing committee ( Development and Manufacturing Committee ) and (b) a Commercialization\ncommittee (\u201c Commercialization Committee \u201d). The Parties acknowledge and agree that the Development and Manufacturing\nCommittee and the Commercialization Committee shall have no authority to amend or modify the terms and conditions of this\nAgreement or the Manufacturing and Supply Agreement\n14.2 Development and Manufacturing Committee .\n14.2.1 Composition of the Development and Manufacturing Committee . The Development and\nManufacturing Committee shall have a total of at least [***] ([***]) members. At least [***] ([***]) of such members shall be\n\nthe Territory, negotiation of wholesaler contracts and negotiations with buyer groups (including group purchasing organizations) and\nkey accounts\u037e (c) negotiating with public and private health insurance companies and governmental authorities regarding the price and\nreimbursement status of the Licensed Products and obtaining and maintaining pricing and reimbursement approvals\u037e (d) marketing,\nmedical affairs, and promotion (including by entertaining a dedicated and sufficiently qualified sales staff, providing for appropriate\nincentive mechanisms for such sales staff, attending relevant conferences, interacting with key opinion leaders, etc.)\u037e (e) set-up of hub\nservices including pre-authorization and reimbursement support and co-pay assist programs\u037e (f) booking of sales and performance of\nrelated services\u037e (g) handling all aspects of order processing, invoicing and collection, inventory and receivables\u037e (h) providing\n\nunenforceability, without invalidating the remainder of such provisions or the remaining provisions of this Agreement, and shall be\nreplaced by a valid and enforceable provisions which comes closest to the commercial intention of the replaced provision.\n16.8 Independent Contractors . Each Party hereby acknowledges that the Parties shall be independent\ncontractors and that the relationship between the Parties shall not constitute a joint venture or\nSource: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020\n\nappointed as follows: each Party shall select one (1) arbitrator, and the two arbitrators so selected by the Parties shall select the third\nand final arbitrator. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator within [***] ([***])\n[***] after the Parties appoint the two arbitrators, then the [***] shall appoint the President of the Tribunal. All arbitrators selected\nshall have the requisite background, experience and expertise in the biopharmaceutical industry to assist with resolution of the dispute.\nPlace of arbitration shall be [***]. Exclusive language of the arbitration proceedings shall be English. Each Party shall bear its own\ncosts and\nSource: COHERUS BIOSCIENCES, INC., 10-K, 2/27/2020",
  "key_terms": "the Territory, negotiation of wholesaler contracts and negotiations with buyer groups (including group purchasing organizations) and\nkey accounts\u037e (c) negotiating with public and private health insurance companies and governmental authorities regarding the price and\nreimbursement status of the Licensed Products and obtaining and maintaining pricing and reimbursement approvals\u037e (d) marketing,\nmedical affairs, and promotion (including by entertaining a dedicated and sufficiently qualified sales staff, providing for appropriate\nincentive mechanisms for such sales staff, attending relevant conferences, interacting with key opinion leaders, etc.)\u037e (e) set-up of hub\nservices including pre-authorization and reimbursement support and co-pay assist programs\u037e (f) booking of sales and performance of\nrelated services\u037e (g) handling all aspects of order processing, invoicing and collection, inventory and receivables\u037e (h) providing\n\nperform its obligations, under this Agreement. The Receiving Party shall not use any of the Disclosing Party\u2019s Confidential\nInformation for any other purpose, and shall not disclose, reveal or otherwise make any of the Disclosing Party\u2019s Confidential\nInformation available to any other person, firm, corporation or other entity, without the prior written authorization of the Disclosing\nParty, except as explicitly stated in this Agreement. An appropriate confidential disclosure agreement must be signed by any Third\nParty or Affiliate prior to receiving Confidential Information from either Party.\n11.2 Additional Obligations . In furtherance of the Receiving Party\u2019s obligations under Section 11.1 hereof, the\nReceiving Party shall take all appropriate steps and shall implement all appropriate safeguards, to prevent the unauthorized use or\ndisclosure of any of the Disclosing Party\u2019s Confidential Information available to any Third Party, without the prior written authorization\n\nshall remain liable for the performance of its obligations under this Agreement.\n16.6 Construction . This Agreement will be fairly interpreted in accordance with its terms and without any strict\nconstruction in favour of or against any Party. The words \u201cinclude\u201d, \u201cincludes\u201d, and \u201cincluding\u201d, \u201csuch as\u201d, \u201cfor example\u201d, or any\nother words or phrases of enumerative meaning shall be deemed to be followed by the phrase \u201c(but without limitation)\u201d.\n16.7 Severability . Whenever possible, each provision of this Agreement shall be interpreted in such manner as to\nbe valid and enforceable under Applicable Laws, but if any provision of this Agreement is held to be prohibited by or invalid or\nunenforceable under Applicable Laws, such provision shall be ineffective only to the extent of such prohibition, invalidity or\nunenforceability, without invalidating the remainder of such provisions or the remaining provisions of this Agreement, and shall be\n\nAgreement shall control, unless otherwise explicitly agreed to in writing by the Parties.\n16.11 Entire Agreement . This Agreement (including the attached Annexes and Schedules) together with the\nManufacturing and Supply Agreement and the Pharmacovigilance Agreement described in Section 4.6 contains the entire\nunderstanding of the Parties with respect to the subject matter hereof. To the extent of any conflict between the terms and conditions\nof this Agreement and the terms and conditions of the Manufacturing and Supply Agreement or Pharmacovigilance Agreement, the\nterms and conditions of this Agreement shall control unless otherwise expressly set forth to the contrary in the Manufacturing and\nSupply Agreement or Pharmacovigilance Agreement. All other express or implied representations, agreements and understandings\nwith respect to the subject matter hereof, either oral or written, heretofore made, are expressly superseded by this Agreement."
}